216 related articles for article (PubMed ID: 2545062)
1. Aggravation of hypoglycemia in insulinoma patients by the long-acting somatostatin analogue octreotide (Sandostatin).
Stehouwer CD; Lems WF; Fischer HR; Hackeng WH; Naafs MA
Acta Endocrinol (Copenh); 1989 Jul; 121(1):34-40. PubMed ID: 2545062
[TBL] [Abstract][Full Text] [Related]
2. Malignant insulinoma: effects of a somatostatin analog (compound 201-995) on serum glucose, growth, and gastro-entero-pancreatic hormones.
Osei K; O'Dorisio TM
Ann Intern Med; 1985 Aug; 103(2):223-5. PubMed ID: 2861769
[No Abstract] [Full Text] [Related]
3. Octreotide exacerbated fasting hypoglycaemia in a patient with a proinsulinoma; the glucostatic importance of pancreatic glucagon.
Gama R; Marks V; Wright J; Teale JD
Clin Endocrinol (Oxf); 1995 Jul; 43(1):117-20; discussion 120-2. PubMed ID: 7641403
[TBL] [Abstract][Full Text] [Related]
4. Chronic treatment of a benign insulinoma using the long-acting somatostatin analogue SMS 201-995.
Glaser B; Rösler A; Halperin Y
Isr J Med Sci; 1990 Jan; 26(1):16-9. PubMed ID: 2155884
[TBL] [Abstract][Full Text] [Related]
5. Malignant insulinoma: is combined treatment with verapamil and the long-acting somatostatin analogue octreotide (SMS 201-995) more effective than single therapy with either drug?
Stehouwer CD; Lems WF; Fischer HR; Hackeng WH
Neth J Med; 1989 Aug; 35(1-2):86-94. PubMed ID: 2550827
[TBL] [Abstract][Full Text] [Related]
6. Remission of symptoms of chemotherapy-refractory metastatic insulinoma using octreotide.
Longnecker SM
Drug Intell Clin Pharm; 1988 Feb; 22(2):136-8. PubMed ID: 2894965
[TBL] [Abstract][Full Text] [Related]
7. A case of malignant insulinoma: successful control of glycemic fluctuation by replacing octreotide injections with octreotide LAR injections.
Okamoto M; Kishimoto M; Takahashi Y; Osame K; Noto H; Yamamoto-Honda R; Kajio H; Tokuhara M; Edamoto Y; Endo H; Igari T; Kubota K; Noda M
Endocr J; 2013; 60(8):951-7. PubMed ID: 23665775
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the long-acting somatostatin analogue octreotide in the management of insulinoma in three dogs.
Simpson KW; Stepien RL; Elwood CM; Boswood A; Vaillant CR
J Small Anim Pract; 1995 Apr; 36(4):161-5. PubMed ID: 7603057
[TBL] [Abstract][Full Text] [Related]
9. [Benign insulinoma. Efficacy of preoperative treatment for persistent hyperinsulinemia using a synthetic somatostatin analog].
Esposito V; Esposito D; Lo Iudice G; Rispoli C; Verrillo A; D'Alessandro B
Minerva Endocrinol; 1994 Mar; 19(1):33-7. PubMed ID: 8035768
[TBL] [Abstract][Full Text] [Related]
10. Long-acting somatostatin analogues in pancreatic islet cell carcinoma.
Souquet JC
Horm Res; 1989; 32(1-3):74-6. PubMed ID: 2559020
[TBL] [Abstract][Full Text] [Related]
11. No effect of the long-acting somatostatin analogue octreotide in patients with insulinoma.
Timmer R; Koningsberger JC; Erkelens DW; Thijssen JH; Lips CJ; Koppeschaar HP
Neth J Med; 1991 Jun; 38(5-6):199-203. PubMed ID: 1922592
[TBL] [Abstract][Full Text] [Related]
12. Severe hypoglycaemia after long-acting octreotide in a patient with an unrecognized malignant insulinoma.
Healy ML; Dawson SJ; Murray RM; Zalcberg J; Jefford M
Intern Med J; 2007 Jun; 37(6):406-9. PubMed ID: 17535385
[TBL] [Abstract][Full Text] [Related]
13. Effect of octreotide on plasma concentrations of glucose, insulin, glucagon, growth hormone, and cortisol in healthy dogs and dogs with insulinoma.
Robben JH; van den Brom WE; Mol JA; van Haeften TW; Rijnberk A
Res Vet Sci; 2006 Feb; 80(1):25-32. PubMed ID: 15946716
[TBL] [Abstract][Full Text] [Related]
14. Successful long-term treatment with once-daily injection of low-dose octreotide in an aged patient with insulinoma.
Katabami T; Kato H; Shirai N; Naito S; Saito N
Endocr J; 2005 Oct; 52(5):629-34. PubMed ID: 16284444
[TBL] [Abstract][Full Text] [Related]
15. Medical treatment of benign insulinoma using octreotide LAR: a case report.
Usukura M; Yoneda T; Oda N; Yamamoto Y; Takata H; Hasatani K; Takeda Y
Endocr J; 2007 Feb; 54(1):95-101. PubMed ID: 17124362
[TBL] [Abstract][Full Text] [Related]
16. [Insulinoma and octreotide].
Stehouwer C
Ned Tijdschr Geneeskd; 1992 Jun; 136(25):1221. PubMed ID: 1614574
[No Abstract] [Full Text] [Related]
17. Octreotide: a long-acting inhibitor of endogenous hormone secretion for human metabolic investigations.
Krentz AJ; Boyle PJ; Macdonald LM; Schade DS
Metabolism; 1994 Jan; 43(1):24-31. PubMed ID: 8289671
[TBL] [Abstract][Full Text] [Related]
18. On the use of a new somatostatin analogue in the treatment of hypoglycaemia in patients with insulinoma.
Verschoor L; Uitterlinden P; Lamberts SW; Del Pozo E
Clin Endocrinol (Oxf); 1986 Nov; 25(5):555-60. PubMed ID: 2887309
[TBL] [Abstract][Full Text] [Related]
19. The use of SMS 201-995 (somatostatin analogue) in insulinomas. Additional case report and literature review.
Hearn PR; Ahmed M; Woodhouse NJ
Horm Res; 1988; 29(5-6):211-3. PubMed ID: 2851522
[TBL] [Abstract][Full Text] [Related]
20. Glucose-responsive and octreotide-sensitive insulinoma.
Izumiyama H; Gotyo N; Fukai N; Ozawa N; Doi M; Yoshimoto T; Arii S; Hirata Y
Intern Med; 2006; 45(8):519-24. PubMed ID: 16702744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
